PANEK JAMES P 4

What Happened

• James P. Panek, a director of Sutro BioPharma (STRO), was granted a derivative award covering 10,000 shares on June 5, 2026. The reported acquisition price is $0.00, indicating an option award or similar equity grant (no cash paid at grant). This was an award/grant transaction (code A), not a purchase or sale.

Key Details

• Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (timely—filed by the second business day).
• Security: derivative (option) for 10,000 shares; reported price $0.00.
• Vesting: 8.33% of the award vests monthly, first tranche vests July 5, 2026; fully vested and exercisable on the earlier of the issuer’s 2027 annual meeting or June 5, 2027.
• Shares owned after transaction: not disclosed in the filing excerpt provided.
• No 10b5-1 plan, exercise price, or immediate sale information was disclosed in this filing.

Context

• This type of grant is common director compensation and does not represent an immediate market purchase or sale. As a derivative award, value to the insider depends on future vesting and any exercise price (not stated here). Such awards are informative about compensation but do not alone indicate the insider’s view on the company’s near-term stock direction.